Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T15:47:40.912Z.
Calculation as of: 2026-10-06T15:47:40.912Z.
Quote observation: 2026-10-06T15:45:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7a3ccde1bd0df5c55ebc0148063105fff0bf751cb52a3071af3e3331f6001fbe
PE RATIO
N/A
Market Cap
$489.14M
PE Ratio
18.62
TTM Avg
12.02
3Y Avg
15.67
5Y Avg
102.65
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Oculis Holding AG (OCS) | $501.67M | N/A | N/A | N/A | N/A |
| Allogene Therapeutics, Inc. (ALLO)vs › | $510.83M | N/A | N/A | N/A | N/A |
| Evolus, Inc. (EOLS)vs › | $493.91M | N/A | N/A | N/A | N/A |
| Puma Biotechnology, Inc. (PBYI)vs › | $489.14M | 18.62 | 12.02 | 15.67 | 102.65 |
| 908 Devices Inc. (MASS)vs › | $515.72M | N/A | 12.07 | 12.07 | 12.07 |
| Arvinas, Inc. (ARVN)vs › | $482.53M | 46.74 | 54.09 | 54.09 | 54.09 |
| Monopar Therapeutics Inc. (MNPR)vs › | $522.07M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $523.14M | N/A | 0.20 | 0.20 | 0.20 |
| Crescent Biopharma, Inc. (CBIO)vs › | $523.17M | N/A | N/A | N/A | N/A |
| Bright Minds Biosciences Inc. (DRUG)vs › | $479.52M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
